AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$1.04 USD
-0.01 (-0.48%)
Updated Oct 10, 2024 03:50 PM ET
After-Market: $1.04 +0.01 (0.48%) 4:44 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.04 USD
-0.01 (-0.48%)
Updated Oct 10, 2024 03:50 PM ET
After-Market: $1.04 +0.01 (0.48%) 4:44 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
by Zacks Equity Research
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
by Zacks Equity Research
AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
by Zacks Equity Research
AN2 Therapeutics, Inc. (ANTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
AN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strategic executions on the United States and the international fronts are likely to drive Walgreens (WBA) Q4 revenues.
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.
Should You Buy AN2 Therapeutics, Inc. (ANTX) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer
by Zacks Equity Research
J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.
J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange
by Zacks Equity Research
J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.